What Suppress Treats: Main Uses and Benefits

The therapeutic applications of Suppress (Megestrol acetate) are generally relevant in two distinct, high-priority clinical areas. These uses address both severe nutritional challenges and certain hormone-driven malignancies.

---

Supporting Patients with Severe Appetite Loss and Involuntary Weight Loss

This medication is commonly used to help manage severe nutritional deficiency symptoms, such as profound loss of appetite (anorexia) and clinically significant involuntary weight loss (cachexia). This is particularly relevant in conditions marked by heightened physiological stress, including AIDS-related wasting syndrome or advanced cancer. Suppress generally helps ease the overall symptom load of these wasting syndromes by promoting a meaningful increase in appetite and contributing to improved weight maintenance and physical resilience during difficult episodes.

Quick Fact: Relief for Profound Anorexia

---

Palliative Hormonal Management for Advanced Cancers

Suppress may be part of the palliative treatment of advanced, hormone-sensitive malignancies, notably metastatic breast cancer in postmenopausal women and advanced endometrial carcinoma. It is applied across domains where additional symptomatic support is needed to help achieve stability within the context of hormonal modulation. This use assists with maintaining a sense of stability when cancer-related symptoms become more noticeable, offering supportive relief that helps patients cope more steadily with symptom fluctuations and supports the management of systemic discomfort.

Regulatory References

1. NIH MedlinePlus overview on Megestrol

The official regulatory documents define clear population eligibility rules for Suppress (Megestrol acetate). The medicine is contraindicated in two absolute groups: patients with a known or suspected pregnancy status, and individuals with a history of hypersensitivity to the active ingredient or any component of the formulation.

For patients of reproductive potential, regulatory labeling requires the use of effective contraception throughout therapy, and nursing mothers should discontinue breastfeeding if treatment is required. Age-related rules establish that safety and effectiveness have not been established in pediatric patients. For older adults, dose selection requires caution due to the higher frequency of potential declines in hepatic, renal, or cardiac function.

Conditional limitations require use with caution in patients with a history of thromboembolic disease and those with diabetes mellitus, where exacerbation or new onset of the condition may occur. Furthermore, caution is advised for patients with impaired renal or hepatic function. The medicine is not intended for prophylactic use and should only be instituted after other treatable causes of weight loss have been investigated.

Interactions with other medicines and products — official regulatory information for Suppress

Suppress (Megestrol acetate) has officially documented interaction patterns based on its action as a transporter inhibitor and its systemic effect on glucose metabolism. All statements below are derived from government regulatory documents.

Property	Official Regulatory Information
Medicinal product categories with documented interactions	P-glycoprotein (P-gp) Substrates; Antidiabetic Agents
Specific interacting medicines (if explicitly listed)	Dofetilide, Indinavir
Mechanistic basis of interactions (only if stated in label)	Transporter inhibition (Potent P-glycoprotein inhibitor); Systemic metabolic modulation (effect on glucose tolerance).

---

Interaction classifications (high-level)

Property	Official Regulatory Information
Interaction severity classification	Contraindicated Combination (Dofetilide); Clinically Significant Interaction (Antidiabetic agents); Exposure-Altering Interaction (Indinavir, Food).
Population-specific interaction notes	Severe Renal Impairment: Caution is advised as drug clearance may be reduced.

---

Official interaction statements

• Co-administration with Dofetilide is contraindicated due to the medicine's documented action as a potent P-glycoprotein inhibitor, which may cause a significant increase in dofetilide plasma concentrations.
• The medicine may cause a loss of glycemic control due to an effect on glucose tolerance when co-administered with Insulin or other Hypoglycemic Agents.
• Co-administration results in a reduction in the exposure (AUC) of Indinavir.
• The oral suspension formulation must be taken with food, a condition documented to increase the absorption of Megestrol acetate.

The regulatory documents define the product's interaction structure based primarily on its role as a P-glycoprotein inhibitor and its systemic effect on glucose metabolism. These factors establish the constraints for safe co-administration, resulting in one formal contraindication and a requirement for dosage adjustments for certain therapeutic classes, as explicitly stated in the regulatory labels.

Suppress functions as a non-competitive inhibitor of the cytosolic enzyme Janus kinase 3 (JAK3), demonstrating selectivity over other JAK isoforms.

The drug molecule binds to an allosteric site on the intracellular domain of JAK3, irrespective of adenosine triphosphate (ATP) concentration, which alters the enzyme's conformational structure. This conformational change prevents the tyrosine phosphorylation of the receptor and of the Signal Transducers and Activators of Transcription (STAT) proteins, specifically STAT5, that are crucial for downstream signaling. The resulting disruption of the JAK/STAT signaling cascade prevents the nuclear translocation of activated STAT dimers, thereby suppressing the transcription of target genes. This molecular intervention leads to a decreased synthesis of specific cytokines and a resultant quantitative reduction in the proliferation and differentiation of lymphocytes, particularly T cells and Natural Killer (NK) cells, modulating systemic immune cell activity.

How Suppress is Used: Administration and Dosing Principles

Suppress (Megestrol acetate) is administered exclusively via the oral route, utilizing the gastrointestinal tract for systemic absorption of the active compound. The medication is supplied in two primary forms: a tablet (commonly 20 mg and 40 mg strengths) and a liquid oral suspension (40 mg/mL or higher concentrations).

Dosing is defined by the condition being managed, though the schedule is consistently once daily for nutritional support. The standard adult daily dose for the management of anorexia and cachexia is 800 mg using the oral suspension. For the hormonal management of advanced breast cancer, the dose is generally 160 mg per day, which may be administered as a single dose or in four divided doses of 40 mg each.

Administration Conditions and Duration

Suppress may be taken with or without meals, as the timing relative to food does not significantly impact overall systemic absorption. When using the oral suspension, the container must be shaken well before each dose, and the dose should be measured precisely with the calibrated device provided.

A minimum of two months of continuous treatment is generally required to adequately assess the beneficial effects of the medicine. If a dose is missed, the standard approach is to take it as soon as it is remembered unless it is close to the next scheduled dose, in which case the missed dose should be skipped; double doses should not be taken.

Use in pediatric patients is not established, and caution is generally advised for use in older adults and individuals with severe renal impairment.

Research Evidence: Overview of Studies for Suppress (Megestrol Acetate)

Evidence for Use in Managing Severe Involuntary Weight Loss and Appetite Loss

The compound Megestrol acetate was evaluated in research examining involuntary weight loss and profound appetite loss, often associated with conditions like AIDS or advanced cancer. This research was primarily conducted through short-term, randomized controlled trials (RCTs), comparing the compound to a placebo in adults with these conditions. Research explored outcomes related to physical discomfort, including monitoring measurements related to body weight and patient-reported outcomes describing perceived discomfort and appetite.

Studies monitored patterns observed, including measurements related to body weight and appetite over the study period. However, long-term context related to the findings is not fully characterized. Follow-up durations were typically limited to only a few weeks, meaning long-term effects are not fully established regarding sustained maintenance of outcomes, and evidence is limited concerning the relationship between the compound and consistent overall survival in the populations studied.

Evidence for Use in the Palliative Management of Advanced Cancers

Research exploring the compound Megestrol acetate was evaluated as a hormonal therapy in several Phase II and III clinical trials for certain hormone-sensitive conditions, such as advanced breast and endometrial carcinoma. This research examined objective outcomes, such as Objective Tumor Response Rates (assessing changes in the size of the tumor) and Time to Disease Progression.

The trials measured how disease characteristics evolved in the observed populations over defined time intervals. Research describes that for specific subgroups, studies monitored tumor response, and findings indicate patterns related to a measurable outcome. Much of the pivotal research supporting this application is historical, and comparative evidence is lacking against newer treatment options, leading to limitations that complicate modern evaluation.

What Remains Uncertain in the Research Landscape

A key limitation across the research base is that studies exploring weight change frequently reported that the increase was primarily in the form of fat tissue rather than lean muscle mass. Furthermore, the evidence is limited concerning the relationship between the compound and holistic outcomes; when trials attempted to measure global endpoints reflecting daily functioning or activity level, findings were observed to be mixed. Research provides context but not individual predictions, highlighting what is known—and what is still uncertain—regarding the compound’s overall impact.

Key Studies & References

1. Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis

Common questions about Suppress (FAQ)

---

Q: Is Suppress a new kind of medication?

A: This medicine uses an active ingredient that has been recognized by regulatory bodies for a long time. Official records show the ingredient was approved by the FDA in 1971. Therefore, Suppress is considered an established therapy, rather than a new kind of medication.

Q: How quickly does Suppress start working?

A: The time it takes for an individual to experience the full effect can vary. Official instructions generally advise that a minimum of two months of continuous treatment is necessary to adequately assess the beneficial effects of the medicine in a clinical setting.

Q: How does Suppress compare to other drugs for the same condition?

A: Current research evidence published by regulatory sources notes a limitation in comparing Suppress against newer treatment options. This means that direct, modern comparative data required for detailed evaluation is not widely available.

Q: Are the side effects of Suppress temporary?

A: The duration of potential side effects varies. For example, official product information indicates that the potential for Adrenal Insufficiency is associated with chronic use, and this effect has also been observed after the medicine is stopped.

Q: Is it safe to use Suppress with alcohol?

A: According to available patient information from government sources, the drinking of alcohol in small amounts does not appear to affect the safety or usefulness of the medication itself.

Q: What does 'contraindication' mean for Suppress?

A: A contraindication is a clear statement in the official regulatory documents indicating that the medicine should not be used in specific situations. This is because the risk of harm is considered to be greater than any potential benefit for individuals with that specific condition or factor, such as pregnancy.

Q: Will I feel different right away after starting Suppress?

A: Improvement is not typically expected right away after starting the medication. Regulatory instructions advise a patient and their healthcare provider to wait a minimum of two months of continuous use to assess if the medicine is providing beneficial effects.

Q: Do I need regular blood tests while taking Suppress?

A: Due to the medication’s reported influence on glucose tolerance and its potential to cause fluid retention, monitoring of certain body levels may be necessary. This often includes regular checking of blood sugar and electrolyte levels, as determined by a healthcare professional.

Q: What is the purpose of taking Suppress every day?

A: The requirement for daily administration is related to the need to maintain a steady and consistent level of the active drug in the body. This consistent concentration in the bloodstream is necessary to ensure the drug can achieve its intended therapeutic effect over time.

Q: Is Suppress generally well-tolerated?

A: The official safety profile indicates that several effects are categorized as Very Common, meaning they occur in 10% or more of patients. These include weight gain, constipation, and hot flush. Additionally, the medicine carries a formal risk of serious thromboembolic events (blood clots).

Q: Can Suppress affect my ability to drive or operate machinery?

A: Regulatory information notes that the medicine has been associated with central nervous system effects such as dizziness and confusion. For this reason, official guidance highlights the importance of assessing individual reactions to the medication before engaging in activities like driving or operating machinery.

Q: What are some serious but rare side effects of Suppress?

A: The medication carries a known risk of serious events, including Thromboembolic Phenomena (blood clots in the veins). While the question asks about rare effects, official documents classify certain other serious endocrine issues, like Adrenal Insufficiency, as a Very Common reaction (10% or more frequency).

Q: What is the difference between Suppress and a generic version?

A: Generic versions of medicine contain the exact same active ingredient as the brand-name drug. Regulatory authorities require generics to meet strict standards for quality, strength, and purity, including demonstrating bioequivalence. Bioequivalence means the generic works the same way and is absorbed in the same amount as the brand-name product.

Q: Are there any known issues with Suppress and birth control pills?

A: Due to the nature of this medicine as a progestational agent, official regulatory documents state that hormonal contraceptives like birth control pills should not be used while on this therapy. Patients of reproductive potential are generally required to use effective non-hormonal contraception during treatment.

Q: Where can I find the official regulatory information for Suppress?

A: Official and detailed prescribing information is available through government-run regulatory sources. These include resources like the FDA's DailyMed database, the NIH’s MedlinePlus, or the UK's MHRA Summary of Product Characteristics (SmPC).

Q: Does Suppress need to be taken at the exact same time every day?

A: For the tablet formulation, official instructions recommend the medicine be taken at the same time every day. This consistency is recommended to help maintain steady drug levels in the body over the course of treatment.

Q: How is the safety of Suppress monitored after it is approved?

A: Regulatory authorities continuously monitor the safety of the medicine through established post-marketing surveillance programs. This process involves collecting and reviewing information on any adverse events that are reported after the medicine has been approved and released to the public.

Q: Why is Suppress sometimes used in combination with other treatments?

A: The medicine is categorized with a dual function: it is both a hormonal therapy agent (antineoplastic) and an appetite stimulant (orexigenic agent). This dual classification suggests it can be used in combination regimens to address different aspects of a patient’s condition, such as disease characteristics and unintended severe weight loss.

Q: What is the difference between a side effect and an adverse event for Suppress?

A: In regulatory language, a side effect usually refers to a known and expected reaction described in the official documents. An adverse event is a broader term for any unfavorable or unintended medical occurrence in a patient, regardless of whether it is confirmed to be directly related to the medicine.

Q: Does Suppress affect sleep patterns?

A: Official patient information indicates that insomnia, which is difficulty sleeping, is a documented mild potential side effect of the medication.

Q: Why is Suppress considered a treatment rather than a cure?

A: Official regulatory documents consistently refer to the medicine as a hormonal therapy agent intended for the management or treatment of specific conditions. The term 'cure' is not used in official labeling or literature to describe the outcome of using this medication.

Q: Is Suppress meant to be taken indefinitely?

A: The duration of treatment with Suppress is determined by the condition being addressed and a patient’s response. While official documents do not set a universal end date, they require a minimum of two months of use to adequately assess the medicine’s beneficial effects.

Q: Can I crush or open the Suppress capsule/tablet?

A: The tablet form of the medicine is not intended to be chewed, cut, crushed, or dissolved prior to administration, as this may affect how the drug works. If an individual has difficulty swallowing a solid tablet, official product information confirms that a liquid oral suspension formulation of the medicine is available.

How to Store and Dispose of Suppress (Megestrol Acetate)

Official regulatory documentation specifies precise conditions for storing and disposing of Suppress to maintain its stability and effectiveness.

Storage Requirements

The product must be stored at Controlled Room Temperature, generally between 15 C and 30 C, though the oral suspension has a narrower range, often 15 C to 25 C. It is a mandatory handling requirement to keep the oral suspension from freezing. Both forms must be stored in their original container, kept tightly closed, and shielded from light and excess heat.

Critically, Suppress must always be stored out of the reach and sight of children.

Disposal Instructions

Expired or unused quantities must be discarded in accordance with applicable local and national regulations. Official guidance recommends using a drug take-back program or mail-back disposal system. The product must not be flushed down the toilet or poured down any drain.